Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in Neisseria gonorrhoeae, United States
Edward Goldstein , Robert D. Kirkcaldy, David Reshef, Stuart Berman, Hillard Weinstock, Pardis Sabeti, Carlos Del Rio, Geraldine Hall, Edward W. Hook, and Marc Lipsitch
Author affiliations: Harvard School of Public Health, Boston, Massachusetts, USA (E. Goldstein, M. Lipsitch); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.D. Kirkcaldy, S. Berman, H. Weinstock); Oxford University, Oxford, UK (D. Reshef); Harvard University, Cambridge, Massachusetts, USA (P. Sabeti); Emory University, Atlanta (C. Del Rio); Cleveland Clinic, Cleveland, Ohio, USA (G. Hall); University of Alabama at Birmingham, Birmingham, Alabama, USA (E.W. Hook); and Jefferson County Department of Health, Birmingham (E.W. Hook)
Figure 3. . . . . Semiannual prevalence of recent travel history in different type carriers for men who have sex with men (A) and heterosexual men (B). Ciprofloxacin (Cipro) sensitive, MIC <0.0625 μm/L.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.